PYGL and disorder of glycogen metabolism: Our DH patient presented with a contraindication to dapsone due to an underlying GSD (type 6 - PYGL mutation) which necessitated a lifetime therapeutic alternative, in contrast to previously reported cases,6 avoiding the risks of dapsone-induced side effects (Table I).4